NXTC NextCure
Price Chart
Executive Summary
NextCure announced positive Phase 1 dose escalation data for SIM0505, a CDH6-targeting ADC, at ASCO 2026, showing a 55% ORR in gynecologic cancers (52.9% in ovarian, 66.7% in USC) at therapeutic doses. The data supports an ongoing dose-optimization study focused on platinum-resistant ovarian cancer, and the FDA has granted Fast Track Designation for PROC. For a $22M market cap clinical-stage biotech, this is a significant pipeline validation event.
Actionable Insight
The 55% ORR in heavily pretreated gynecologic cancers significantly exceeds the 10-25% standard-of-care benchmark for PROC, suggesting potential best-in-class positioning. Monitor the June 2 KOL event for expert context and the dose-optimization data readout for confirmation of efficacy durability. The Fast Track designation supports an accelerated regulatory path.
Key Facts
- 55% ORR (11/20) in gynecologic cancers at therapeutic doses (4.8-8.0 mg/kg) per RECIST 1.1 at 12 weeks
- 52.9% ORR (9/17) in ovarian cancer; 66.7% ORR (2/3) in uterine serous carcinoma
- FDA Fast Track Designation granted for SIM0505 in platinum-resistant ovarian cancer
- Phase 1 dose optimization initiated May 2026 in PROC; global study to enroll up to 120 patients
- Favorable safety profile: Grade 3/4 TEAEs predominantly hematological and manageable; only 3 dose discontinuations due to TRAEs
- NextCure holds exclusive global rights excluding China/HK/Macau/Taiwan (retained by Simcere Zaiming)
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue
Risk Factors
- Early-stage data (Phase 1 dose escalation, n=20 evaluable at therapeutic dose) — ORR may not replicate in larger Phase 2/3 trials
- Two of nine ovarian PRs are unconfirmed or pending confirmation; durability of responses unknown
- Competing CDH6 ADCs (e.g., from other developers) could limit market share
- NextCure has no approved products and relies on partnerships and financing; cash runway not disclosed
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304283 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
8-K
| $3.38 $3.40 | ▲ +0.59% | ▲ +0.45% | $2.95 (−12.72%) |
|
Jun 1, 2026
4d ago
|
Press Release
| $3.38 $3.40 | ▲ +0.59% | ▲ +0.45% | $2.95 (−12.72%) |
|
May 7, 2026
29d ago
|
8-K
| $9.76 $9.78 | ▲ +0.20% | ▼ −0.03% | $2.95 (−69.77%) |
|
May 4, 2026
4w ago
|
Press Release
| $8.92 $9.32 | ▲ +4.48% | ▲ +3.69% | $2.95 (−66.93%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $9.62 $9.25 | ▼ −3.85% | ▼ −3.36% | $2.95 (−69.33%) |
|
Apr 21, 2026
6w ago
|
Press Release
| $10.97 $12.00 | ▲ +9.39% | ▲ +8.37% | $2.95 (−73.11%) |
|
Mar 5, 2026
13w ago
|
8-K
| $12.39 $12.51 | ▲ +0.97% | ▲ +0.12% | $2.95 (−76.19%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $12.39 $12.51 | ▲ +0.97% | ▲ +0.12% | $2.95 (−76.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access